Johns Hopkins University

Boston University

The University of New Mexico

Institut National De La Sante Et De La Recherche Medicale

Memorial Sloan Kettering Cancer Center

The City University of New York

William R Bishai

Laurene Cheung

John R Murphy

Cynthia K Bullen

Shashank Gupta

Bappaditya Dey

James DeMaio

Ruchi Jain Dey

Graham Timmins

Douglas B Young

Ying Zhang

Drew M Pardoll

Derek Shieh Tan

Vojo P Deretic

Gyanu Lamichhane

Juan Fu

Seong Won Choi

Michel Arthur

Marie Lavollay

Trinity J Bivalacqua

Pankaj Kumar

Jean-Luc Mainardi

Shichun Lun

Amit Kumar

Sadiya Parveen

Sumit Siddharth

Dipali Sharma

Alok Singh

Sharon Master

James E Gomez

Glennon Valere Bythrow

Radhika Gupta

Vijayan Sambasivam

Zachary Sharp

Viorel Atudorei

Takahiro Yoshida

Mamoudou Maiga

Monali Praharaj

Lisa Charlotte Standke

Luis Edmundo Nereo Quadri

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts or tautomers thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment and/or prevention of an infectious disease (e.g., bacterial infection (e.g.,infection (e.g., tuberculosis)). (I)

Salicyl-adenosinemonosulfamate analogs and uses thereof

Described are methods of suppressing the expression of myeloid-derived suppressor cells (MDSCs), M2 macrophages, and Treg cells in a tumor and inducing the expression of macrophages, dendritic cells (DCs), and T effector cells in a tumor in a subject. A pharmaceutical composition comprising a strain ofincluding an expression vector of the present invention is administered to a subject.

Recombinant therapeutic interventions for cancer

The present invention is related to a method of treating or preventing cancer in a subject comprising administering to a subject having cancer or prone of getting cancer a first agent that depletes the subject's regulatory T cells (Tregs); followed by administering to the subject a second agent comprising a checkpoint inhibitor.

Methods of treating or preventing cancer with an agent that depletes tregs and a checkpoint inhibitor

The present invention is a DNA expression vector comprising: a toxP: a mutant toxO that blocks Fe-mediated regulation of gene expression; and a DNA sequence encoding a protein, wherein the toxP and the mutant toxO regulate expression of the DNA segment encoding the protein. It is preferred that DNA expression vectors of the present invention include DNA sequences encoding a signal peptide so that a protein expressed is attached to the signal peptide prior to processing. Novel proteins are produced off of the DNA expression vector of the present invention.

Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses

The present invention includes the discovery of a strain ofcomprising an expression vector encoding a di-adenylate cyclase enzyme. Theis selected from the group consisting of, or a combination thereof and the preferred strain ofis BCG. The preferred expression vector is a mycobacterial expression vector including an hsp60 promoter and a DNA sequence of diadenylate cyclase (disA), or a functional part thereof. The strains ofare used in therapeutic applications including tuberculosis and cancer.

Methods of treating cancer using bacteria expressing c-di-AMP

The present invention is a DNA expression vector comprising: a toxP; a mutant toxO that blocks Fe-mediated regulation of gene expression; and a DNA sequence encoding a protein, wherein the toxP and the mutant toxO regulate expression of the DNA segment encoding the protein. It is preferred that DNA expression vectors of the present invention include DNA sequences encoding a signal peptide so that a protein expressed is attached to the signal peptide prior to processing. Novel proteins are produced off of the DNA expression vector of the present invention.

Described herein are methods of treating or preventing cancer in a subject comprising administering to the subject an effective amount of a bacteria comprising and expression vector encoding a di-adenylate cyclase enzyme.

Bacteria over-expressing c-di-AMP and therapeutic methods

The present invention is directed to methods of diagnosing the presence or absence of a bacterial infection in a patient, in particular, a tuberculosis infection, by measuring exhaled, isotopically labeled nitrogen gas after administration of isotopically labeled isoniazid.

Methods of using isotopically labelled isoniazid for the diagnosis of mycobacterial infections

The peptidoglycan layer is a vital component of the bacterial cell wall, which comprises 4&#x2192;3 and 3&#x2192;3 transpeptide cross-linkages, the formation of which are catalyzed by D,D- and L,D-transpeptidases, respectively. Methods for the treatment of bacterial infections with agents that inhibit L,D-transpeptidases, either alone or in combination with D,D-transpeptidase inhibitors, are provided herein. Also provided are methods for the treatment of chronic stage tuberculosis with agents that inhibit enzyme with L,D-transpeptidase activity.

Methods for treatment of bacterial infections

The present invention relates to the use of isotopically labeled derivatives of isoniazid, ethionamide and related compounds as effective therapy for the treatment of mycobacterial diseases, including

Rationally improved isoniazid and ethionamide derivatives and activity through selective isotopic substitution

A whmD gene that controls sporulation in mycobacteria, vectors and transformed cells containing the gene.

whmD, an essential cell division gene from mycobacteria

sigF is a gene that controls M. tuberculosis latency. A diagnostic test for latent tuberculosis involves detecting M. tuberculosis sigF in clinical specimens. Two genes orfX and orfY regulate sigF expression and sigF activity. M. tuberculosis sigF, orfX, and orfY are used in screening methods for potential therapeutic agents which regulate the growth of M. tuberculosis.

Method of identifying compounds that regulate the binding of M.

Two genes, orfX and orfY, regulate sigF expression and sigF activity in M. tuberculosis. M. tuberculosis sigF, orfX, and orfY are used in screening methods for potential therapeutic agents which regulate the growth of M. tuberculosis.

Regulation of a sigma factor from Mycobacterium tuberculosis

Growing community of inventors

Baltimore, MD, United States of America

William R Bishai